<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207804</url>
  </required_header>
  <id_info>
    <org_study_id>FIM</org_study_id>
    <nct_id>NCT01207804</nct_id>
  </id_info>
  <brief_title>Feasibility Trial of ValenTx Endo Bypass System</brief_title>
  <official_title>A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ValenTx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ValenTx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to provide initial clinical data to support the feasibility of
      use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in
      morbidly obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center open label feasibility study to evaluate the safety, efficacy and
      performance of the ValenTx Endo Bypass system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device performance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ValenTx Endo Bypass System</intervention_name>
    <description>Patient is implanted with device and followed for 12 weeks</description>
    <arm_group_label>Device</arm_group_label>
    <other_name>ValenTx</other_name>
    <other_name>Endo Bypass System</other_name>
    <other_name>EBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 55 years of age

          -  &gt;=35 kg/m2 and &lt;= 50 kg/m2, with or without comorbid conditions(s).

          -  Documented failure with non-surgical weight loss methods

          -  Willing to comply with study procedures and visit schedule

          -  Willing and able to provide Informed Consent

        Exclusion Criteria:

          -  Pregnancy or intention of becoming pregnant within the study duration.

          -  Endoscopic lesions such as important hiatal hernia, gastric or duodenal ulcer,
             atresias or stenosis, polyps of the stomach.

          -  Subject with potential upper gastrointestinal bleeding such as esophageal or gastric
             varices, Mallory-Weis syndrome or congenital or acquired intestinal telangiectasia.

          -  Past history of esophageal or gastric/GI surgery, obstruction, adhesive peritonitis,
             or large hiatal hernia (&gt; 3 cm).

          -  IBS, unexplained intermittent vomiting, severe abdominal pain or chronic constipation
             within 60 days of study day 1

          -  Unexplained anaemia, Pancreatitis, Portal hypertension, Esophagitis or Barrett's
             esophagus, known gallstones or anomalies of the GI tract

          -  Any bodily infections within 30 days of study day 1.

          -  Prolonged steroid use

          -  Hep C or HIV positive

          -  Known allergies to any of the device materials

          -  Use of weight loss medication or an investigational drug or device within 2 months
             prior to enrolment and throughout the study period.

          -  Recent or ongoing cancer, history of severe renal, hepatic, cardiovascular or
             pulmonary disease or transplants

          -  Inability to tolerate anti-inflammatory medications

          -  Evidence of psychiatric problems or dietary habits that would contraindicate study
             treatment;

          -  Active drug or alcohol addiction within 12 months of enrolment and throughout the
             study duration.

          -  Prior history of inflammatory diseases of the GI tract, (e.g., esophagitis, varices,
             gastric or duodenal ulceration, or Crohn's disease; congenital or acquired GI
             anomalies, e.g., bowel strictures)

          -  Ongoing treatment with anticoagulants, steroids, aspirin, NSAIDs, or other gastric
             irritants within 1 month prior to enrollment and throughout the study period.

          -  Participation in previous (within 60 days of study day 1) or ongoing clinical trial or
             current or past usage (within 60 days of study day 1) of investigation drug or device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Rumbaut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Jose Tec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Jose Tec de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

